دورية أكاديمية
أعرض في EDS

Doxorubicin-Loaded Core-Shell UiO-66@SiO 2 Metal-Organic Frameworks for Targeted Cellular Uptake and Cancer Treatment.

التفاصيل البيبلوغرافية
العنوان: Doxorubicin-Loaded Core-Shell UiO-66@SiO 2 Metal-Organic Frameworks for Targeted Cellular Uptake and Cancer Treatment.
المؤلفون: Trushina DB; Federal Research Center Crystallography and Photonics, Russian Academy of Sciences, 119991 Moscow, Russia.; Department of Biomedical Engineering, Sechenov First State Medical University, 119991 Moscow, Russia., Sapach AY; Department of Biomedical Engineering, Sechenov First State Medical University, 119991 Moscow, Russia.; Center for Neurobiology and Brain Restoration (CNBR), Skolkovo Institute of Science and Technology, 143025 Moscow, Russia., Burachevskaia OA; The Smart Materials Research Institute, Southern Federal University, 344090 Rostov-on-Don, Russia., Medvedev PV; The Smart Materials Research Institute, Southern Federal University, 344090 Rostov-on-Don, Russia., Khmelenin DN; Federal Research Center Crystallography and Photonics, Russian Academy of Sciences, 119991 Moscow, Russia., Borodina TN; Federal Research Center Crystallography and Photonics, Russian Academy of Sciences, 119991 Moscow, Russia., Soldatov MA; The Smart Materials Research Institute, Southern Federal University, 344090 Rostov-on-Don, Russia., Butova VV; The Smart Materials Research Institute, Southern Federal University, 344090 Rostov-on-Don, Russia.
المصدر: Pharmaceutics [Pharmaceutics] 2022 Jun 23; Vol. 14 (7). Date of Electronic Publication: 2022 Jun 23.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101534003 Publication Model: Electronic Cited Medium: Print ISSN: 1999-4923 (Print) Linking ISSN: 19994923 NLM ISO Abbreviation: Pharmaceutics Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI
مستخلص: Beneficial features of biocompatible high-capacity UiO-66 nanoparticles, mesoporous SiO 2 , and folate-conjugated pluronic F127 were combined to prepare the core-shell UiO-66@SiO 2 /F127-FA drug delivery carrier for targeted cellular uptake in cancer treatment. UiO-66 and UiO-66-NH 2 nanoparticles with a narrow size and shape distribution were used to form a series of core-shell MOF@SiO 2 structures. The duration of silanization was varied to change the thickness of the SiO 2 shell, revealing a nonlinear dependence that was attributed to silicon penetration into the porous MOF structure. Doxorubicin encapsulation showed a similar final loading of 5.6 wt % for both uncoated and silica-coated particles, demonstrating the potential of the nanocomposite's application in small molecule delivery. Silica coating improved the colloidal stability of the composites in a number of model physiological media, enabled grafting of target molecules to the surface, and prevented an uncontrolled release of their cargo, with the drawback of decreased overall porosity. Further modification of the particles with the conjugate of pluronic and folic acid was performed to improve the biocompatibility, prolong the blood circulation time, and target the encapsulated drug to the folate-expressing cancer cells. The final DOX-loaded UiO-66@SiO 2 /F127-FA nanoparticles were subjected to properties characterization and in vitro evaluation, including studies of internalization into cells and antitumor activity. Two cell lines were used: MCF-7 breast cancer cells, which have overexpressed folate receptors on the cell membranes, and RAW 264.7 macrophages without folate overexpression. These findings will provide a potential delivery system for DOX and increase the practical value of MOFs.
References: Mol Pharm. 2009 Mar-Apr;6(2):407-15. (PMID: 19718794)
Front Immunol. 2020 Mar 04;11:218. (PMID: 32194546)
J Am Chem Soc. 2008 Nov 5;130(44):14358-9. (PMID: 18844356)
J Am Chem Soc. 2014 Apr 9;136(14):5181-4. (PMID: 24669930)
ACS Appl Mater Interfaces. 2021 May 5;13(17):19701-19709. (PMID: 33900738)
J Am Chem Soc. 2008 Oct 22;130(42):13850-1. (PMID: 18817383)
ACS Appl Mater Interfaces. 2020 Sep 2;12(35):38989-39004. (PMID: 32805901)
Chemistry. 2015 Feb 2;21(6):2508-18. (PMID: 25504892)
J Control Release. 2008 Sep 10;130(2):98-106. (PMID: 18534704)
J Mater Chem B. 2020 Jul 28;8(28):6128-6138. (PMID: 32568335)
Nanotechnology. 2021 May 12;32(29):. (PMID: 33853047)
Acc Chem Res. 2008 Jan;41(1):120-9. (PMID: 17655275)
Adv Mater. 2012 Dec 18;24(48):6433-7. (PMID: 23001882)
Inorg Chem. 2021 Apr 19;60(8):5694-5703. (PMID: 33830750)
Biomaterials. 2015 Aug;61:266-78. (PMID: 26005765)
Langmuir. 2017 May 30;33(21):5253-5260. (PMID: 28489388)
J Am Chem Soc. 2008 Sep 3;130(35):11584-5. (PMID: 18686947)
Sci Rep. 2014 Nov 14;4:7053. (PMID: 25394493)
Drug Discov Today. 2017 Feb;22(2):270-281. (PMID: 27890669)
Mikrochim Acta. 2019 Feb 20;186(3):196. (PMID: 30788595)
Nature. 2013 Aug 22;500(7463):486-9. (PMID: 23851396)
Chem Sci. 2016 Aug 1;7(8):5294-5301. (PMID: 30155180)
Chem Soc Rev. 2021 May 7;50(9):5397-5434. (PMID: 33666625)
Nanomaterials (Basel). 2018 Oct 23;8(11):. (PMID: 30360511)
Chem Commun (Camb). 2012 Sep 28;48(75):9388-90. (PMID: 22892418)
Langmuir. 2011 Aug 2;27(15):9535-40. (PMID: 21732647)
J Am Chem Soc. 2009 Oct 14;131(40):14261-3. (PMID: 19807179)
Acc Chem Res. 2011 Oct 18;44(10):957-68. (PMID: 21648429)
Chem. 2017 Apr 13;2(4):561-578. (PMID: 28516168)
Nanoscale. 2018 Mar 29;10(13):6205-6211. (PMID: 29560986)
Int J Mol Sci. 2021 Jan 14;22(2):. (PMID: 33466760)
Chem Soc Rev. 2015 Oct 7;44(17):6287-305. (PMID: 26056687)
J Colloid Interface Sci. 2013 Feb 15;392:288-296. (PMID: 23137909)
J Am Chem Soc. 2008 Jul 23;130(29):9216-7. (PMID: 18576625)
J Am Chem Soc. 2014 Dec 3;136(48):16712-5. (PMID: 25407895)
J Am Chem Soc. 2014 May 14;136(19):6786-9. (PMID: 24786337)
Chem Commun (Camb). 2014 Aug 14;50(63):8779-82. (PMID: 24967656)
معلومات مُعتمدة: 19-73-10069 Russian Science Foundation; 21-74-10058 Russian Science Foundation
فهرسة مساهمة: Keywords: MOF; UiO-66; chemotherapy; doxorubicin; folate receptors; nano-MOF; nanoparticles; silanization; silica shell; tumor targeting
تواريخ الأحداث: Date Created: 20220727 Latest Revision: 20220731
رمز التحديث: 20221213
مُعرف محوري في PubMed: PMC9324125
DOI: 10.3390/pharmaceutics14071325
PMID: 35890221
قاعدة البيانات: MEDLINE
الوصف
تدمد:1999-4923
DOI:10.3390/pharmaceutics14071325